In the second phase III trial, previously untreated patients with metastatic melanoma were treated with ipilimumab plus dacarbazine
According to the results of these analyses, eribulin demonstrated a trend for extension in overall survival over dacarbazine
in each subtype.
Results: The results exhibited that sea cucumber saponin, dacarbazine
, and coadministration of saponin-dacarbazine
inhibited the proliferation of melanoma cells in a dose and time dependent manner with [IC.
5 mg / kg [right arrow] P 50 mg / kg) C:Control , P: Treatment with Propolis, T1:Treatment with Dacarbazine
, P+T1:Treatment with Propolis & Dacarbazine
In a study of 502 patients, a combination of ipilimumab (Yervoy) and dacarbazine
was used to stimulate the immune system to fight tumors.
It's unprecedented to report a trial this early," said lead author Paul Chapman, MD, of Memorial Sloan-Kettering Cancer Center, adding that the dacarbazine
patients were allowed to cross over to vemurafenib treatment group (i.
This study compared ipilimumab plus dacarbazine
Currently, melanoma patients who are treated with chemotherapeutic agent dacarbazine
had a median survival of 7 months to 8 months, he said.
The patients will be randomized on a 2:1 basis: approximately 250 patients will be treated with Allovectin-7(r) and approximately 125 will be treated with their physician's choice of either of two chemotherapy agents, dacarbazine
Bridgewater, NJ) announced the availability of Genasense (oblimersen sodium) Injection for use incombination with dacarbazine
through an Expanded Access Program for eligible patients in the United States with advanced melanoma who have not previously received chemotherapy.
Recent studies show that combination therapy with mesna, doxorubicin, ifosfamide, and dacarbazine
or combination therapy with cyclophosphamide, doxorubicin, vincristine, and dacarbazine
is effective against soft-tissue sarcomas.
Zelboraf was approved by FDA in August 2011, following positive results of an interim analysis of BRIM3, a global, randomized, open-label, controlled Phase 3 study that compared Zelboraf to dacarbazine
(chemotherapy), in 675 patients with previously untreated BRAF V600E mutation-positive, unresectable (inoperable) or metastatic melanoma.
The NEMO trial (NCT01763164), is an international, randomised Phase 3 study evaluating the safety and efficacy of 45 mg BID binimetinib, compared to 1,000 mg/m2 dacarbazine
dosed every three weeks.
The CHMP's positive opinion is based on the results from Phase III study (Study 309)(1)comparing the efficacy and safety of Halaven versus dacarbazine
in 452 patients (aged 18 or over) with locally advanced or recurrent and metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma) who had disease progression following standard therapies which must have included an anthracycline and at least one other additional regimen.
Patient was started on 6 cycles of Dacarbazine